Nilofar Rahman, MD RISK OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION WITH PPI USE.

Slides:



Advertisements
Similar presentations
Antibiotic Stewardship Curriculum Developed by: Vera P. Luther, M.D.
Advertisements

Population- based Surveillance of Reportable Diseases in Nursing Home Facilities in Nebraska Manjiri Joshi, MPH + Alison Keyser Metobo, MPH + + Epidemiology.
David N. Juurlink, et al. CMAJ 2009;180: (7) [Epub]
Clostridium difficile Presented by Nate Smith, MD, MPH Carole Yeung, RN CIC.
C. Difficile and Fecal Microbiota Therapy
2013 CLOSTRIDIUM DIFFICILE EDUCATIONAL AND CONSENSUS CONFERENCE March 11-12, 2013.
ICS in COPD – A Risk Factor for CAP? Rate of pneumonia in ICS Studies
Management of Clostridium difficile Infections
Progress in Diagnosing and Treating Clostridium difficile in IBD patients Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine Director of.
Antimicrobials and risks for antibiotic-associated diarrhea (AAD) Antibiotic-associated diarrhea 5-30% risk Higher with multiple IV drugs Higher with broad.
What do case-control studies tell us about risk factors for antibiotic resistance? Christie Y. Jeon EPI502 Jan 22 nd, 2008.
Monday AM report
Leav, B. A., et al.(2010) “Serum Anti-toxin B Antibody Correlates with Protection from Recurrent Clostridium Difficile Infection (CDI)”. Vaccine 28:
Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.
Clostridium difficile Prevention and Treatment Katrina Beining & Christina Gardner Introduction Clostridium difficile (C. diff) is a gram-positive, spore-forming.
Top 5 Papers in Infectious Diseases Pharmacotherapy: A Review of 2013 for the General Practitioner Sharanie V. Sims, Pharm.D., BCPS (AQ-ID) Infectious.
ADP Receptors Bhatt DL et al. Nature Reviews Drug Discovery 2003; 2:15-28.
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Multi-centre, retrospective cohort study in 308 nursing homes reporting ≥1 confirmed or suspected norovirus outbreak (USA; ) Primary endpoints:
Effect of prolonging Clostridium difficile (CD) treatment on recurrence rate in patients receiving concomitant systemic antibiotic therapy 5-yr retrospective.
The Influence of Proton Pump Inhibitors on Clinical Outcomes After Successful Percutaneous Coronary Intervention Kishore J. Harjai, MD, FACC Chetan Shenoy,
The Association between blood glucose and length of hospital stay due to Acute COPD exacerbation Yusuf Kasirye, Melissa Simpson, Naren Epperla, Steven.
Clostridium difficile Separating key facts from fiction S P Borriello
Frequency of Clostridium difficile infection (CDI) transmission via ward contact with a known case Retrospective, observational study (22 months; 1 laboratory.
To screen or not to screen – Clostridium difficile Simon Goldenberg, Consultant Microbiologist Guy’s & St Thomas’ NHS Foundation Trust.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Treatment duration and outcomes for male urinary tract infection (UTI) Retrospective review of 33,336 patients with index UTI from Veterans Affairs database.
Lec. No. 11 Dr. Manahil Clostridium difficile C. difficile is a gram positive, spore forming, obligate anaerobe. Colonies of the organism are about 4mm.
R1 김동연 /prof. 이창균. Introduction  Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high.
Frequency of Clostridium difficile transmission by asymptomatic carriers during hospital admission Study 1: Transmission by asymptomatically colonised.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
Coffee and Tea Intake Appears Protective Against Chronic Liver Disease Slideset on: Ruhl CE, Everhart JE. Coffee and tea consumption are associated with.
Joseph J.Y. Sung, MD et al. Am J Gastroenterol 2010;105. R3 김민경.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
© 2013 Pearson Education, Inc. Bell Ringer  What is an endospore, and what special characteristics do endospore forming bacteria have?
Table S1. Logistic regression analysis for the variables associated with the degree of change in cTnT between 2 time points (n=89) UnivariateMultivariate.
JAMA Internal Medicine May 2015 Volume 175, Number5 R1 조한샘 / Prof. 이창균.
Clostridium difficile infection (CDI) in the ICU and Clostridium difficile outcomes in the PROSPECT Main Trial Erick Duan MD FRCPC Presented at the CCCTG.
- Higher SBP visit-to-visit variability (SBV) has been associated
and brain injured patients in an inpatient rehabilitation hospital
Alison Keyser Metobo, MPH +
C. difficile Detection and the Importance of Proper Specimen Collection and Testing [Name] [Title]
Clinical outcome after SVR: Veterans Affairs
Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection  F. Cao, C.X. Chen, M. Wang,
Introduction to epidemiology (and infection)
More Than Survival: Futility
Update on Clostridium difficile Infection
Outcomes with trisodium citrate 30% vs heparin as catheter-locking solution (all catheters) in patients on hemodialysis Variable TSC, n (%) Heparin, n.
Jeffrey F. Barletta, PharmD, Shareen Y. El-Ibiary, PharmD, Lindsay E
Oral Vancomycin as a Therapeutic Option for PSC
Management of Clostridium Difficile Infection
Presenter: Wen-Ching Lan Date: 2018/03/28
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
David L. McCollum, J. Martin Rodriguez 
Probiotics in the Prevention of C Difficile Infection
Treatment Update on Clostridium difficile Infection
Prospective Cohort Study of Body Image Disturbance in Surgically-Managed Head and Neck Cancer Patients Evan Graboyes MD Department of Otolaryngology-Head.
Treatment of Clostridium difficile-Associated Disease
Patient characteristics: American vs Canadian transplant patients
Microbiologic factors affecting Clostridium difficile recurrence
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
C.P. Kelly  Clinical Microbiology and Infection 
Trends and Outcomes Associated With Serum Albumin Concentration Among Incident Dialysis Patients in the United States  George A. Kaysen, MD, PhD, Kirsten.
E. Tacconelli  Clinical Microbiology and Infection 
Specimens submitted, tested, and rejected during the postintervention period. aAfter ordering clinician discussion with the laboratory. bPatient treated.
A Single Participant Exposed Twice to an Inflammatory Stimulus
Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes  Steven M. Brunelli, Ravi Thadhani,
Risk factors for postoperative infection after lower gastrointestinal surgery in patients with inflammatory bowel disease: Findings from a large epidemiological.
Increased incidence rate ratio (IRR) and 95% confidence intervals (CI) for type-specific community-acquired infections across eGFR categories within 12.
Presentation transcript:

Nilofar Rahman, MD RISK OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION WITH PPI USE

CLOSTRIDIUM DIFFICILE ORGANISM  Identified in 1978  “J strain”  B1/NAP1/027 strain

INCIDENT RATES IF C. DIFF. INFECTION

EPIDEMIOLOGY OF C. DIFF INFECTION

RISK FACTORS FOR RECURRENCE OF CDI  Advanced age  Non- CDI targeted antibiotic exposure  Longer hospital stay  Inadequate antitoxin-antibody response  Concomitant use of PPIs

PATHOGENESIS OF C. DIFF INFECTION Antibiotic therapy Disruption of gut flora Toxin production C. Diff exposure

PROBABILITY OF RECURRENCE OF C. DIFF WITH VANC.(TOP) AND METRONIDAZOLE(BELOW)

STUDY DONE BY LINSKY ET AL. STUDY DESIGN 1549 Incident c. diff toxin 1408 treated with oral metronidazole or vancomycin 1166 treated within 3 d before or after index CDI 527 PPI exposure639 no PPI exposure

Study population

PRIMARY EXPOSURE AND OUTCOMES  Exposure measure : PPI within 14 days  Outcome measure: C. diff toxin in after incident CDI  Covariates:  Age, sex  Comorbid conditions  CDI- targeted antibiotic  Non-CDI targeted antibiotic

RESULTS

ModelHazard ratio(95% CI)P value Unadjusted1.42( )0.006 Adjusted1.42( )0.008 Non-CDI antibiotic exposure 1.71( )0.01 No antibiotic exposure 1.30( )0.12 RESULTS CONTD..

Study done by Kim et al.

EXPOSURE VARIABLE AND STUDY DESIGN  Exposure variable: PPI use 3D prior to CDI Study design Recurrent group Non-recurrent group

RESULTS  Age > 65 (60%, P=0.02)  Fed via NGT (48.1%, P=0.04)  Low albumin ( 2.3+/- 0.5g/dl vs /- 0.4g/dl)  PPI use (63% vs 39.8%, P=0.01) UNIVARIATE ANALYSIS

RISK FACTORSADJUSTED ODDS RATIO CI (95%)P VALUE Age> Concurrent PPI use Serum albumin<2.5g/dl NGT MULTIVARIATE ANALYSIS

Since use of PPIs is a modifiable risk factor for recurrence it is appropriate to review, constantly, the use of PPIs in patients with CDI.

THANK YOU

REFERENCES